Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Autor: Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou

Publikováno v: Thoracic Cancer, Vol 15, Iss 5, Pp 419-426 (2024)

Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and

Externí odkaz: https://doaj.org/article/5593cfcf22cf4de189ad661dbe843899

Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

Autor: Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu

Publikováno v: Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)

Abstract This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab–chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical sta

Externí odkaz: https://doaj.org/article/fac0f07d3dc04d809e388bf7352818af

Emerging evidence and treatment paradigm of non-small cell lung cancer

Autor: Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li, Yi-Long Wu

Publikováno v: Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-20 (2023)

Abstract Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalize

Externí odkaz: https://doaj.org/article/ea64f79867e24340851b91a0764ca52b

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors

Autor: Dingwei Ye, Jayesh Desai, Jingwen Shi, Si-Yang Maggie Liu, Wei Shen, Tengfei Liu, Yang Shi, Dan Wang, Liang Liang, Silu Yang, Xiaopeng Ma, Wei Jin, Pei Zhang, Ruiqi Huang, Zhirong Shen, Yun Zhang, Yi-Long Wu

Publikováno v: Biomarker Research, Vol 11, Iss 1, Pp 1-12 (2023)

Abstract Background Activated immune cells (IC) in the tumor microenvironment (TME) are critical for anti-tumor efficacy. Greater understanding of the dynamic diversity and crosstalk between IC is needed to clarify their association with immune check

Externí odkaz: https://doaj.org/article/48b24d1af75c492dafcdc3284ea4b0f0

A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer

Autor: Yichao Han, Si-Yang Maggie Liu, Runsen Jin, Wangyang Meng, Yi-Long Wu, Hecheng Li

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

BackgroundComprehensive analysis of transcriptomic profiles of non-small cell lung cancer (NSCLC) may provide novel evidence for biomarkers associated with response to PD-1/PD-L1 immune checkpoint blockade (ICB).MethodsWe utilized weighted gene co-ex

Externí odkaz: https://doaj.org/article/7d4ca81b3ed54bafaf7bf73443c79212